StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) stock

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$5.94−0.08 (-1.33%)

Close on Nov 18, 2026Market cap $1.30BP/E –Yield –

Ocular Therapeutix revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Ocular Therapeutix's revenue for the twelve months ending Jun 30, 2026 was $52.05M, down 8.1% year over year. For fiscal 2025 it was $51.95M, down 18.5% from the year before. Over ten years it grew 40.4% a year on average. The highest annual figure on record is $63.72M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$51.95M-18.5%
FY2024Dec 31, 2024$63.72M+9.0%
FY2023Dec 31, 2023$58.44M+13.5%
FY2022Dec 31, 2022$51.49M+18.3%
FY2021Dec 31, 2021$43.52M+150.1%
FY2020Dec 31, 2020$17.40M+311.7%
FY2019Dec 31, 2019$4.23M+112.4%
FY2018Dec 31, 2018$1.99M+3.5%
FY2017Dec 31, 2017$1.92M+1.9%
FY2016Dec 31, 2016$1.89M+7.8%
FY2015Dec 31, 2015$1.75M+126.7%
FY2014Dec 31, 2014$772.00K+7620.0%
FY2012Dec 31, 2012$10.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$13.48M+0.1%
Q1 FY2026Mar 31, 2026$10.79M+0.8%
Q4 FY2025Dec 31, 2025$13.25M-22.4%
Q3 FY2025Sep 30, 2025$14.54M-5.7%
Q2 FY2025Jun 30, 2025$13.46M-18.1%
Q1 FY2025Mar 31, 2025$10.70M-27.6%
Q4 FY2024Dec 31, 2024$17.08M+15.4%
Q3 FY2024Sep 30, 2024$15.43M+2.3%
Q2 FY2024Jun 30, 2024$16.44M+8.3%
Q1 FY2024Mar 31, 2024$14.77M+10.5%
Q4 FY2023Dec 31, 2023$14.80M+5.2%
Q3 FY2023Sep 30, 2023$15.08M+26.0%
Q2 FY2023Jun 30, 2023$15.19M+23.8%
Q1 FY2023Mar 31, 2023$13.37M+1.4%
Q4 FY2022Dec 31, 2022$14.08M+14.4%
Q3 FY2022Sep 30, 2022$11.97M-1.5%
Q2 FY2022Jun 30, 2022$12.27M+4.7%
Q1 FY2022Mar 31, 2022$13.19M+79.6%
Q4 FY2021Dec 31, 2021$12.31M+67.5%
Q3 FY2021Sep 30, 2021$12.15M+106.8%
Q2 FY2021Jun 30, 2021$11.72M+646.8%
Q1 FY2021Mar 31, 2021$7.34M+181.4%
Q4 FY2020Dec 31, 2020$7.35M+225.8%
Q3 FY2020Sep 30, 2020$5.88M+608.8%
Q2 FY2020Jun 30, 2020$1.57M+141.4%
Q1 FY2020Mar 31, 2020$2.61M+430.3%
Q4 FY2019Dec 31, 2019$2.26M+347.6%
Q3 FY2019Sep 30, 2019$829.00K+66.5%
Q2 FY2019Jun 30, 2019$650.00K+0.3%
Q1 FY2019Mar 31, 2019$492.00K+44.7%
Q4 FY2018Dec 31, 2018$504.00K+3.5%
Q3 FY2018Sep 30, 2018$498.00K-4.8%
Q2 FY2018Jun 30, 2018$648.00K+47.9%
Q1 FY2018Mar 31, 2018$340.00K-28.4%
Q4 FY2017Dec 31, 2017$487.00K-4.7%
Q3 FY2017Sep 30, 2017$523.00K+9.6%
Q2 FY2017Jun 30, 2017$438.00K–
Q1 FY2017Mar 31, 2017$475.00K–
Q4 FY2016Dec 31, 2016$511.00K–
Q3 FY2016Sep 30, 2016$477.00K–

More Ocular Therapeutix figures

See a number that looks wrong?